Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Stephen L HauserAmit Bar-OrJeffrey A CohenGiancarlo ComiJorge CorrealePatricia K CoyleAnne H CrossJerome de SezeDavid LeppertXavier MontalbanKrzysztof SelmajHeinz WiendlCecile KerloeguenRoman WilliBingbing LiAlgirdas KakariekaDavorka TomicAlexandra GoodyearRatnakar PingiliDieter A HäringKrishnan RamanathanMartin MerschhemkeLudwig Kapposnull nullPublished in: The New England journal of medicine (2020)
Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II ClinicalTrials.gov numbers, NCT02792218 and NCT02792231.).